AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01222715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study NCT03740685 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High sesitive C reactive protien
Description: High sesitive C reactive protien will be evaluated at admission time and after 36 hours
Study NCT02056405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride
Description: 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
Study NCT02056405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
Study NCT00990119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm High Flow Therapy
Description: use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
Study NCT00990119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Description: Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
Study NCT00733421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: 100 mg twice daily
Study NCT02811510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill (no active cannabinoids)
Study NCT02811510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: 10 mg capsule of Dronabinol will be administered orally.
Study NCT01598272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitality product AM + Vitality product PM
Description: Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
Study NCT01598272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
Study NCT01760135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high caloric nutritional supplement
Description: high caloric nutritional supplement (25kcal/kg)
Study NCT01760135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low caloric nutritional supplement
Description: low caloric nutritional supplement(15kcal/kg)
Study NCT01805089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 mg
Description: Melatonin vs. Placebo
Study NCT01805089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 3 mg
Description: Melatonin vs. Placebo
Study NCT00191477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Study NCT00191477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Study NCT03760107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 1
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study NCT01916096 — intervention group
Intervention type: DEVICE
Intervention: Delica Device
Study NCT00629252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: oral 12-20 mg/day
Study NCT00629252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: oral 2-6mg / day
Study NCT03161470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Repositioning
Description: It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
Study NCT03161470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Chair Repositioning
Description: It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
Study NCT03161470 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
Study NCT01620138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months.
Study NCT01620138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline
Description: The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months.
Study NCT01962103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
Study NCT01962103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion
Study NCT00030901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-selenomethionine
Description: Randomization between active L-selenomethionine and placebo
Study NCT03760107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 2
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study NCT03760107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 3
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study NCT03760107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 4
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study NCT03760107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 5
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study NCT03760107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 6
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study NCT01533272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir, emtricitabine, maraviroc
Description: experimental drug
Study NCT01533272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir, emtricitabine, lopinavir/r
Description: Lopinavir/r 400mg BID
Study NCT01303874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Description: ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
Study NCT01303874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ETN-matching placebo SC injections once weekly and MTX orally once weekly.
Study NCT01255722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iobitridol
Description: single IV injection
Study NCT01255722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iopromide
Description: Single IV injection
Study NCT01255722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iomeprol
Description: Single IV injection
Study NCT04624061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated HIV/HTN care model
Description: The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
Study NCT03239795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement
Description: Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT03387852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study NCT04178551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation Facilitation
Description: The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
Study NCT02730819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Illuminate Cream
Description: Topical compound applied daily
Study NCT04321720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-g mustard footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
Study NCT04321720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-g mustard footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
Study NCT04321720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-g mustard footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
Study NCT04321720 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Warm water only
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
Study NCT02345512 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lycra Splinting Garment
Description: Wearing of lycra splinting garment for 6 weeks
Study NCT01433198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic training
Description: Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
Study NCT03235583 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MOTIONPODTM device validation
Description: MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
Study NCT00714168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Program
Description: This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
Study NCT00714168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care Weight Loss Program
Description: In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
Study NCT03478891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMAB092-00-AB (MAb114)
Description: VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
Study NCT00901290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monophasic oral contraceptive
Description: mg, oral dose
Study NCT00901290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: mg, oral dose
Study NCT02997566 — intervention group
Intervention type: OTHER
Intervention: Autonomic evaluation
Study NCT00502125 — intervention group
Intervention type: PROCEDURE
Intervention: Reflectance Confocal Imaging
Description: A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
Study NCT02099006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Topical application of the drug at a 2% concentration in combination with 2% Baclofen
Study NCT00030901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-selenomethionine placebo
Description: Randomization between active L-selenomethionine and placebo
Study NCT05148130 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
Study NCT04421066 — intervention group
Intervention type: PROCEDURE
Intervention: Gingival and bone sample collection
Description: Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.
Study NCT04421066 — intervention group
Intervention type: PROCEDURE
Intervention: Healthy individuals
Description: Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
Study NCT01604954 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrient-label
Description: A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
Study NCT01604954 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calorie-label
Description: A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers.
Study NCT01604954 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No label
Description: Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
Study NCT01893983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Coaching
Description: Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
Study NCT02134691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Study NCT02134691 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Relaxation
Study NCT02872545 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in forward tilted
Description: Rest tomoscintigraphy in forward tilted position
Study NCT02872545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rest tomoscintigraphy in forward tilted
Description: Rest tomoscintigraphy in forward tilted position
Study NCT01538056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenestrated Endovascular Graft or Company Manufactured Terumo Aortic Fenestrated TREO Endovascular Graft
Description: PMEG endovascular graft with fenestrations or the Company Manufactured Terumo Aortic Fenestrated TREO Abdominal Stent Graft System to allow for blood flow to vital visceral vessels such as the renal arteries, celiac, and SMA (Superior Mesenteric Artery).
Study NCT04440579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Description: PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
Study NCT02872545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rest tomoscintigraphy in semi sitting position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
Study NCT02872545 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in semi sitting position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
Study NCT02872545 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in dorsal decubitus position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
Study NCT02099006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Used topically at 2% concentration in combination with 2% amitriptyline
Study NCT02099006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: To be applied topically at a 10% concentration
Study NCT02099006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: To be applied topically at a 10% concentration
Study NCT02872545 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rest tomoscintigraphy in dorsal decubitus position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
Study NCT03559010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestrel 0.075 mg tablets
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet.
Study NCT00293826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 50mg via SC (subcutaneous) injection every 4 weeks
Study NCT00293826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 250mg via SC (subcutaneous) injection every 4 weeks
Study NCT00293826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 125mg via SC (subcutaneous) injection every 4 weeks
Study NCT00293826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via SC (subcutaneous) injection every 4 weeks
Study NCT02099006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: To be applied topically at a 5% concentration
Study NCT02099006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: To be applied topically at a 6% concentration